General Internal Medicine, Cleveland Clinic Medicine Institute, Cleveland, OH.
Am J Kidney Dis. 2010 Mar;55(3 Suppl 2):S15-22. doi: 10.1053/j.ajkd.2009.09.034.
Albuminuria is an important marker for chronic kidney disease and progression to end-stage renal disease in the general population; understanding racial and ethnic differences can help inform efforts to reduce health disparities. We sought to estimate independent associations of race/ethnicity with albuminuria to determine whether observed differences were attributable to known kidney disease risk factors.
This cross-sectional study included 64,161 Kidney Early Evaluation Program (KEEP) participants, 2000-2008, with estimated glomerular filtration rate > or = 60 mL/min/1.73 m(2), not on regular dialysis therapy, and without a previous kidney transplant. Albuminuria (urine albumin-creatinine ratio > or = 30 mg/g) was examined by self-reported race and ethnicity. Covariates were age, sex, educational level, body mass index, diabetes status or glucose level, hypertension status or blood pressure measurement, smoking status, health insurance status, and geographic region.
Albuminuria prevalences were 8% (n = 2,303) in whites, 11% (n = 2,310) in African Americans, 9% (n = 730) in Hispanics, 10% (n = 381) in Asians, and 15% (n = 344) in American Indians/Alaska Natives. Compared with whites, odds of albuminuria were higher for all groups after multivariate adjustment. Odds were highest for American Indians/Alaska Natives (adjusted OR, 1.93; 95% CI, 1.70-2.20), then Asians (adjusted OR, 1.42; 95% CI, 1.26-1.61), African Americans (adjusted OR, 1.38; 95% CI, 1.29-1.47), and Hispanics (adjusted OR, 1.19; 95% CI, 1.08-1.31).
In the KEEP study population, albuminuria prevalence was higher in African Americans, Hispanics, Asians, and American Indians/Alaska Natives than in non-Hispanic whites, suggesting a need for screening for early detection of kidney damage, especially in people at increased risk, in the community primary care setting.
蛋白尿是慢性肾脏病和终末期肾病的重要标志物,在普通人群中;了解种族和民族差异有助于减少健康差距。我们试图估计种族/民族与蛋白尿的独立关联,以确定观察到的差异是否归因于已知的肾脏疾病危险因素。
本横断面研究纳入了 64161 名肾脏早期评估计划(KEEP)参与者,2000-2008 年,肾小球滤过率估计值≥60 mL/min/1.73 m(2),未接受常规透析治疗,且无既往肾移植史。蛋白尿(尿白蛋白/肌酐比值≥30mg/g)通过自我报告的种族和民族进行检查。协变量为年龄、性别、教育程度、体重指数、糖尿病状态或血糖水平、高血压状态或血压测量、吸烟状态、医疗保险状况和地理位置。
白蛋白尿患病率分别为 8%(n=2303)的白人、11%(n=2310)的非裔美国人、9%(n=730)的西班牙裔、10%(n=381)的亚洲人和 15%(n=344)的美洲印第安人/阿拉斯加原住民。与白人相比,调整后的多变量后,所有组的蛋白尿几率均较高。美洲印第安人/阿拉斯加原住民的几率最高(调整后的 OR,1.93;95%CI,1.70-2.20),其次是亚洲人(调整后的 OR,1.42;95%CI,1.26-1.61)、非裔美国人(调整后的 OR,1.38;95%CI,1.29-1.47)和西班牙裔(调整后的 OR,1.19;95%CI,1.08-1.31)。
在 KEEP 研究人群中,非裔美国人、西班牙裔、亚洲人和美洲印第安人/阿拉斯加原住民的白蛋白尿患病率高于非西班牙裔白人,这表明需要进行筛查,以便在社区初级保健环境中尽早发现肾脏损伤,尤其是在高危人群中。